Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Misset, J. L.
Right arrow Articles by Fumoleau, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Misset, J. L.
Right arrow Articles by Fumoleau, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:1123-1129, 2004
© 2004 European Society for Medical Oncology

Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors

Background: This phase I and pharmacokinetic study of pemetrexed in combination with oxaliplatin was performed to determine the maximum tolerated dose (MTD), and to evaluate safety and pharmacokinetics in patients with metastatic solid tumors.

Patients and methods: Pemetrexed was administered as a 10- min i.v. infusion followed 30 min later by oxaliplatin as a 2- h infusion, once every 21 days. Up to two previous chemotherapy regimens were allowed. Vitamin B12 supplementation and folic acid were not included in this study.

Results: Thirty-six patients were treated in six escalating dose levels. Dose-limiting toxicities at dose level 6 (pemetrexed 500 mg/m2 plus oxaliplatin 130 mg/m2) were febrile neutropenia, grade 3–4 diarrhea and grade 3 paresthesia. The MTD was not reached. The most common toxicity was neutropenia, with grade 3–4 occurring in 61% of patients. The pharmacokinetics of this pemetrexed–oxaliplatin combination are consistent with those following single-agent administration. Five responses (all partial) were observed over a broad range of solid tumors.

Conclusions: This pemetrexed–oxaliplatin combination (without vitamin supplementation) every 21 days can be administered using full therapeutic doses of each agent with acceptable tolerability and no overlapping toxicity. The recommended regimen for phase II studies is pemetrexed 500 mg/m2 plus oxaliplatin 120 mg/m2.

J. L. Misset1,*, E. Gamelin2, M. Campone3, S. Delaloge4, J. E. Latz5, L. Bozec6 and P. Fumoleau3

1 Hôpital Saint Louis, Paris; 2 Centre Paul Papin, Angers; 3 Centre René Gauducheau Nantes, St Herblain; 4 Institut Gustave Roussy (IGR), Villejuif, France; 5 Eli Lilly and Company, Indianapolis, IN, USA; Eli Lilly and Company, Suresnes, France

*Correspondence to: Dr J. L. Misset, Division of Medical Oncology, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 7501 Paris, France. Tel: +33-1-42-49-99-38; Fax: +33-1-42-49-91-97; Email: jean-louis.misset{at}sls.ap-hop-paris.fr

Key words: oxaliplatin, pemetrexed, pharmacokinetic, phase I study


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
L. Celio, C. N. Sternberg, R. Labianca, I. La Torre, V. Amoroso, C. Barone, G. Pinotti, S. Cascinu, F. Di Costanzo, G. L. Cetto, et al.
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study
Ann. Onc., June 1, 2009; 20(6): 1062 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Muller, R. Schibli, E. P. Krenning, and M. de Jong
Pemetrexed Improves Tumor Selectivity of 111In-DTPA-Folate in Mice with Folate Receptor-Positive Ovarian Cancer
J. Nucl. Med., April 1, 2008; 49(4): 623 - 629.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
K. Puto and J. S Garey
Pemetrexed Therapy for Malignant Pleural Mesothelioma
Ann. Pharmacother., April 1, 2005; 39(4): 678 - 683.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. V. Scagliotti, C. Kortsik, G. G. Dark, A. Price, C. Manegold, R. Rosell, M. O'Brien, P. M. Peterson, D. Castellano, G. Selvaggi, et al.
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non-Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
Clin. Cancer Res., January 15, 2005; 11(2): 690 - 696.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.